Loading…
Pulmatrix, Inc. is projected to rise to $1.52 by 2027, a +12% move from its current price of $1.36. PULM is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean neutral.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $1.32 | $1.36 | $1.40 | -0.02% |
| May 30 | $1.30 | $1.36 | $1.42 | -0.03% |
| May 31 | $1.29 | $1.36 | $1.43 | -0.05% |
| Jun 1 | $1.28 | $1.36 | $1.44 | -0.06% |
| Jun 2 | $1.27 | $1.36 | $1.45 | -0.08% |
| Jun 3 | $1.26 | $1.36 | $1.46 | -0.10% |
| Jun 4 | $1.26 | $1.36 | $1.47 | -0.11% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.26 | $1.36 | $1.47 | -0.11% |
| Week 2 | $1.21 | $1.36 | $1.52 | -0.23% |
| Week 3 | $1.18 | $1.36 | $1.55 | -0.34% |
| Week 4 | $1.16 | $1.35 | $1.58 | -0.45% |
| Week 5 | $1.13 | $1.35 | $1.61 | -0.56% |
| Week 6 | $1.11 | $1.35 | $1.64 | -0.68% |
| Week 7 | $1.10 | $1.35 | $1.66 | -0.79% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Pulmatrix, Inc. is a biopharmaceutical company focused on the development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. It offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
The company engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor compounds.
The company was founded in 2003 and is headquartered in Framingham, Massachusetts.
Pulmatrix, Inc. (PULM) operates in the Healthcare sector and is currently priced at $1.34 with a market cap of $4.89M, ranking 5349 by market capitalization.
The near-term technical backdrop shows a NEUTRAL stance with RSI(14) at 50, and trend indicators where the 50-day simple moving average sits at $1.46 and the 200-day simple moving average at $3.27. A defined support level exists at $1.21 and a resistance level at $1.40, with a 30-day price range from $1.09 to $1.65.
Forecasted price paths across multiple years reveal a path from stable near-term values toward meaningful longer-term upside. The 2026-2029 window centers around modest activity, while 2030 onward shows bullish momentum with an avg price of $1.78 and a max of $2.67 (ROI 32.5%), rising to 2040 with an avg of $3.87 and a max of $6.86 (ROI 188.6%), and reaching 2050 with an avg of $7.76 and a max of $15.18 (ROI 479.4%). These figures imply a longer-term upside potential, though forecasts are estimates and not guarantees.
A major floor 13.7% below — a decisive break under it would weaken the trend.
The nearest floor, 8.8% below — buyers have tended to step in here.
Price is pressing into resistance (2.9% away) — a breakout level to watch.
A major ceiling 144.9% above — clearing it would confirm fresh momentum.
Key PULM support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PULM market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.34 | Buy | $1.33 | Buy |
| MA 10 | $1.30 | Buy | $1.32 | Buy |
| MA 20 | $1.30 | Buy | $1.32 | Buy |
| MA 50 | $1.42 | Sell | $1.52 | Sell |
| MA 100 | $1.95 | Sell | $2.05 | Sell |
| MA 200 | $3.23 | Sell | $2.97 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 51.81 | Neutral |
| Stoch RSI (14) | 93.77 | Sell |
| CCI (20) | 113.77 | Buy |
| Williams %R (14) | -8.33 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | 4.86 | Buy |
| Bollinger %B (20,2) | 0.87 | Neutral |
| Stochastic %K (14) | 91.67 | Sell |
| TRIX (15) | -0.49 | Sell |
| Awesome (5,34) | 0.04 | Buy |
| Ultimate (7,14,28) | 69.54 | Neutral |
| Momentum (10) | 0.11 | Buy |
| Aroon Osc (25) | -16.00 | Sell |
| Hull MA (9) | 1.37 | Sell |
| ADX (14) | 17.29 | Neutral |
| ATR (14) | 0.03 | Info |
The 30-day technical picture is NEUTRAL with RSI(14) at 50. The 50-day simple moving average is $1.46 and the 200-day simple moving average is $3.27, indicating mixed medium-term momentum.
Support sits at $1.21 and resistance at $1.40, framing a recent trading range. The 30-day price window runs from a low of $1.09 to a high of $1.65, underscoring a relatively tight near-term range with notable volatility implied by an annualized volatility of 60%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.19 | $1.36 | $1.85 | 0% | Neutral | |
| $1.19 | $1.52 | $2.05 | +12% | Neutral | |
| $1.17 | $1.54 | $2.16 | +13% | Neutral | |
| $1.12 | $1.51 | $2.18 | +11% | Neutral | |
| $1.28 | $1.75 | $2.61 | +29% | Bullish | |
| $1.53 | $2.14 | $3.25 | +57% | Bullish | |
| $1.62 | $2.31 | $3.58 | +70% | Bullish | |
| $1.75 | $2.54 | $4.01 | +87% | Bullish | |
| $1.70 | $2.52 | $4.04 | +85% | Bullish | |
| $1.68 | $2.52 | $4.11 | +86% | Bullish | |
| $2.30 | $3.72 | $6.47 | +174% | Bullish | |
| $3.89 | $7.19 | $13.74 | +429% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $1.19 | $1.36 | $1.60 | +0.00% |
| June 2026 | $1.18 | $1.38 | $1.67 | +1.80% |
| July 2026 | $1.13 | $1.34 | $1.64 | -3.20% |
| August 2026 | $1.11 | $1.33 | $1.65 | -0.74% |
| September 2026 | $1.15 | $1.38 | $1.73 | +3.90% |
| October 2026 | $1.16 | $1.40 | $1.76 | +1.27% |
| November 2026 | $1.14 | $1.39 | $1.77 | -0.56% |
| December 2026 | $1.19 | $1.45 | $1.85 | +4.15% |
Click any year to see its month-by-month PULM forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, PULM is projected to trade between $1.19 and $1.85, averaging $1.36 — a potential gain of 0% from today's $1.36. A consolidation phase looks the most probable path here.
Pulmatrix, Inc.'s 2027 outlook centres on $1.52, within a $1.19 to $2.05 range. That is up +12% on the projected 2026 average. That marks a +12% change versus current levels. Price action looks broadly range-bound.
By 2028, PULM could reach as high as $2.16, with a base case around $1.54 and support toward $1.17 — roughly +13% from $1.36. A consolidation phase looks the most probable path here.
Expect PULM to range from $1.12 to $2.18 through 2029. The $1.51 average target implies a +11% move from current prices. That is -2% versus the projected 2028 average. Price action looks broadly range-bound.
The PULM price prediction for 2030 points to an average of $1.75 (low $1.28, high $2.61) — a potential gain of +29% on today's $1.36. Buyers look set to stay in control over this stretch.
In 2031, PULM is projected to trade between $1.53 and $3.25, averaging $2.14 — a potential gain of +57% from today's $1.36. That is up +22% on the projected 2030 average. Momentum favours further upside here.
Pulmatrix, Inc.'s 2032 outlook centres on $2.31, within a $1.62 to $3.58 range. That is up +8% on the projected 2031 average. That marks a +70% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, PULM could reach as high as $4.01, with a base case around $2.54 and support toward $1.75 — roughly +87% from $1.36. Momentum favours further upside here.
Expect PULM to range from $1.70 to $4.04 through 2034. The $2.52 average target implies a +85% move from current prices. That is -1% versus the projected 2033 average. Buyers look set to stay in control over this stretch.
The PULM price prediction for 2035 points to an average of $2.52 (low $1.68, high $4.11) — a potential gain of +86% on today's $1.36. Momentum favours further upside here.
In 2040, PULM is projected to trade between $2.30 and $6.47, averaging $3.72 — a potential gain of +174% from today's $1.36. That is up +47% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Pulmatrix, Inc.'s 2050 outlook centres on $7.19, within a $3.89 to $13.74 range. That is up +93% on the projected 2040 average. That marks a +429% change versus current levels. Momentum favours further upside here.
Investing $1,000 in PULM today (≈ 735.294118 PULM) could be worth
$5,286.03
+$4,286.03 (+429%) by 2050 · US Dollar
Based on the average projected PULM price of $7.19 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PULMwould be worth at today's price.
$1,000 invested in PULM on May 27, 2025 (≈ 129.19897 PULM) would be worth
$175.71
-$824.29 (-82.4%) today · 0.18× · US Dollar
Based on a PULM entry price of $7.74 vs. today's $1.36.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.27 | $1,070.87 | +7.1% |
| 1 month ago | $1.33 | $1,022.56 | +2.3% |
| 3 months ago | $2.91 | $467.35 | -53.3% |
| 6 months ago | $4.45 | $305.62 | -69.4% |
| 1 year ago | $7.74 | $175.71 | -82.4% |
| All time (5.0y) ago | $18.64 | $72.96 | -92.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PULM forecast.
Our base-case forecast reaches $2.70 around 2040.
Implied market cap at $2.70: $9.86M
The multi-year forecast shows a bullish trajectory starting in 2030, with an average price of $1.78, a minimum of $1.28, a maximum of $2.67, and a 32.5% ROI, alongside a bullish sentiment. By 2040, the average is projected at $3.87 with a max of $6.86 and an 188.6% ROI, still under bullish sentiment. In 2050, the average reaches $7.76 with a max of $15.18 and a 479.4% ROI, continuing the bullish outlook.
These are estimates, not guarantees, and reflect potential long-term upside with higher average prices and sizable ROI in later years while acknowledging near-term variability.
Tap a question to reveal the answer.
2030 avg $1.78; min $1.28; max $2.67; ROI 32.5%; sentiment BULLISH.
The long-term outlook is BULLISH with 2030 avg $1.78 (ROI 32.5%), 2040 avg $3.87 (ROI 188.6%), and 2050 avg $7.76 (ROI 479.4%), though forecasts are estimates and not guarantees.
Yes; the forecast max in 2050 is $15.18, which exceeds $5. The 2040 max is $6.86 and the 2030 max is $2.67.
Current price is $1.34; Market cap is $4.89M.
Sentiment NEUTRAL; RSI14 50; SMA50 $1.46; SMA200 $3.27; support $1.21; resistance $1.40; 30-day range $1.09-$1.65; annualized volatility 60%.
Pulmatrix, Inc. Community Discussion
0Share your Pulmatrix, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.